Mitotane Not Needed With Low- to Intermediate-Risk Adrenocortical Carcinoma : vimarsana.com

Mitotane does not show a significant improvement in the relapse rate and is associated with adverse events in patients with adrenocortical carcinoma considered to be at low-to-intermediate risk for recurrence.

Related Keywords

Italy , Massimo Terzolo , University Of Turin , Healthday News , Lancet Diabetes ,